HFNC is Generally Contraindicated in Pneumothorax
High-flow nasal cannula (HFNC) should be avoided in patients with untreated pneumothorax due to the risk of worsening air leak and potential tension pneumothorax from positive airway pressure generation.
Key Safety Concern
HFNC generates positive end-expiratory pressure (PEEP) in the upper airways, typically 2-8 cm H₂O depending on flow rates, which can:
- Worsen existing pneumothorax by increasing pleural air accumulation
- Convert a simple pneumothorax into a tension pneumothorax
- Delay lung re-expansion even with chest tube drainage
Clinical Decision Algorithm
Absolute Contraindications
- Untreated pneumothorax (no chest tube in place)
- Tension pneumothorax (requires immediate needle decompression, not HFNC)
Relative Contraindications Requiring Extreme Caution
- Treated pneumothorax with chest tube - HFNC may be considered only if:
- Chest tube is functioning properly with continuous drainage
- No ongoing air leak or minimal stable air leak
- Close monitoring available for clinical deterioration
- Alternative respiratory support options have been exhausted
When HFNC Might Be Considered (After Pneumothorax Treatment)
- Pneumothorax fully resolved on imaging
- Chest tube removed with confirmed lung re-expansion
- Patient requires respiratory support for underlying condition (e.g., hypoxemic respiratory failure)
Evidence Base
The 2022 ERS guidelines 1 extensively address HFNC use in acute respiratory failure but do not include pneumothorax as an indication. The guidelines focus on hypoxemic respiratory failure, post-extubation support, and hypercapnic respiratory failure—notably excluding pneumothorax from all recommendations.
Pediatric studies document pneumothorax as a recognized complication of HFNC therapy. One pediatric ICU study reported 2 new pneumothoraces (1%) requiring chest tube insertion among 177 HFNC episodes 2. Another German survey found 17.9% of pediatric clinics experienced severe complications including pneumothorax with HFNC use 3. A Pakistani study reported pneumothorax development in 4 of 120 patients receiving HFNC 4.
The 2024 joint ERS/EACTS/ESTS pneumothorax guidelines 5, 6 make no mention of HFNC as a treatment modality, focusing instead on conservative management, needle aspiration, chest tube drainage, and surgical interventions.
Critical Pitfalls to Avoid
- Never initiate HFNC without chest imaging if pneumothorax is suspected
- Do not assume small pneumothoraces are safe - positive pressure can rapidly enlarge them
- Avoid HFNC in blunt chest trauma until pneumothorax is definitively ruled out (though one retrospective study 7 described HFNC use in chest trauma, this was after pneumothorax exclusion or treatment)
- Monitor continuously if HFNC is used with treated pneumothorax - watch for sudden deterioration, increased work of breathing, or hemodynamic instability
Practical Approach
If a patient with pneumothorax requires respiratory support:
- First-line: Conventional oxygen therapy (nasal cannula, simple mask) - generates no positive pressure
- Second-line: Consider non-invasive ventilation (NIV) only after chest tube placement and with extreme caution
- HFNC: Reserve for after complete pneumothorax resolution when respiratory support remains necessary for the underlying condition
The physiologic mechanism of HFNC—generating positive airway pressure to improve oxygenation and reduce work of breathing 1—is the exact reason it poses danger in pneumothorax. This positive pressure can force additional air into the pleural space through any existing pleural defect.